Vaxcyte is a brand dedicated to vaccine innovation and pushing the boundaries of what's possible. Their mission is to eliminate bacterial infections, protecting every child born and every adult at risk across the globe. With a focus on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella, Vaxcyte strives to make a significant impact.

One of their flagship products is VAX-24, a 24-valent pneumococcal conjugate vaccine that addresses non-vaccine strains of Streptococcus pneumoniae. It has been granted FDA Breakthrough Therapy designation for the prevention of invasive pneumococcal disease in adults. Vaxcyte is re-engineering how vaccines are made by using advanced chemistry and their XpressCF™ cell-free protein synthesis platform to produce vaccines that break down bacteria's complex defense mechanisms while preserving immunogenicity.

They are also building a pipeline of high-fidelity and broad-spectrum vaccines. In addition to VAX-24, they are developing VAX-31, a 31-valent PCV candidate, and have preclinical vaccine candidates targeting Group A Strep, periodontitis, and Shigella. With their commitment to innovation and impact, Vaxcyte is at the forefront of vaccine development and disease prevention